

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## DIAGNOSTICS ASSESSMENT PROGRAMME

### Equality impact assessment – Scoping

#### ImmunoCAP ISAC and Microtest for multiplex allergen testing

The impact on equality has been assessed during this assessment according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (scoping workshop discussion, assessment subgroup discussion), and, if so, what are they?

IgE levels may be higher in people with various autoimmune disorders such as Lupus (SLE), Rheumatoid Arthritis (RA) & psoriasis.

People with autoimmune disorders may be protected under the disability provision of the Equality Act 2010.

There is wide variation in access to allergy specialists and allergy care, including challenge testing, across the UK.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

IgE levels may be higher in people with various autoimmune disorders such as Lupus (SLE), Rheumatoid Arthritis (RA) & psoriasis was considered not relevant to the assessment because it would not impact testing.

People with autoimmune disorders may be protected under the disability provision of the Equality Act 2010, however this was considered not relevant the assessment because this would not impact allergy testing.

There is wide variation in access to allergy specialists and allergy care, including challenge testing, across the UK. This was highlighted as a potential equality issue and will be considered by the committee.

--

3. Has any change to the draft scope been agreed to highlight potential equality issues?

In section 6, the wide variation in access to allergy specialists and allergy care, including challenge testing, across the UK has been highlighted.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders have been identified.

**Approved by Associate Director (name):** Carla Deakin

.

**Date:** 16 April 2015